Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis

•Patients with chronic liver disease increasingly use direct oral anticoagulants (DOACs) to prevent or treat thrombosis.•DOACs increase the international normalized ratio, a laboratory test used to prioritize patients for a donor liver.•The model of end-stage liver disease score used for this prioritization process is substantially affected by DOACs.•Measures to fairly and adequately prioritize waitlisted patients using DOACs are needed.